Nova Leap Health Corp. (TSXV:NLH)
Canada · Delayed Price · Currency is CAD 0.5300
0.00 (0.00%)
Sep 14, 2026, 9:30 AM EST
Nova Leap Health Ratios and Metrics
Market cap in millions CAD. Fiscal year is January - December.
Millions CAD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 46 | 24 | 24 | 26 | 22 | 48 | |
Market Cap Growth | 85.96% | 3.70% | -8.85% | 20.00% | -55.44% | -1.71% |
Enterprise Value | 51 | 26 | 23 | 27 | 24 | 45 |
Last Close Price | 0.53 | 0.28 | 0.27 | 0.30 | 0.25 | 0.61 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 24.83 | - | 11.89 | - | - | 21.71 |
Forward PE | - | 18.95 | 18.95 | 6.05 | 6.16 | 16.07 |
PS Ratio | 0.97 | 0.57 | 0.64 | 0.75 | 0.56 | 1.80 |
PB Ratio | 1.68 | 0.94 | 0.90 | 1.08 | 0.85 | 2.07 |
P/TBV Ratio | - | 12.43 | 9.98 | 6.46 | 10.27 | - |
P/FCF Ratio | 16.20 | 11.46 | 12.02 | 9.21 | 16.77 | 17.53 |
P/OCF Ratio | 16.20 | 11.46 | 11.81 | 9.09 | 15.60 | 17.53 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.06 | 0.61 | 0.63 | 0.79 | 0.64 | 1.66 |
EV/EBITDA Ratio | 14.35 | 12.11 | 14.21 | 20.76 | - | - |
EV/EBIT Ratio | 20.62 | 17.44 | 18.78 | 44.86 | - | - |
EV/FCF Ratio | 17.70 | 12.40 | 11.90 | 9.71 | 19.04 | 16.22 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.23 | 0.15 | 0.14 | 0.08 | 0.21 | 0.34 |
Debt / EBITDA Ratio | 1.80 | 1.51 | 1.75 | 1.04 | 13.50 | - |
Debt / FCF Ratio | 2.17 | 1.88 | 1.85 | 0.66 | 4.18 | 2.84 |
Net Debt / Equity Ratio | 0.16 | 0.08 | 0.06 | 0.03 | 0.14 | 0.24 |
Net Debt / EBITDA Ratio | 1.41 | 0.90 | 0.98 | 0.51 | -39.44 | -7.92 |
Net Debt / FCF Ratio | 1.47 | 0.92 | 0.82 | 0.24 | 2.84 | 2.05 |
Asset Turnover | 1.36 | 1.37 | 1.19 | 1.17 | 1.11 | 0.96 |
Quick Ratio | 0.63 | 0.89 | 0.96 | 1.43 | 0.92 | 0.91 |
Current Ratio | 0.70 | 0.96 | 1.06 | 1.59 | 1.00 | 0.96 |
Return on Equity (ROE) | 7.07% | -1.02% | 7.56% | -5.72% | -4.50% | 12.43% |
Return on Assets (ROA) | 4.37% | 3.01% | 2.49% | 1.28% | -2.62% | -3.47% |
Return on Invested Capital (ROIC) | 5.85% | 5.55% | 3.45% | 2.30% | -4.79% | -4.87% |
Return on Capital Employed (ROCE) | 8.50% | 5.60% | 4.50% | 2.40% | -5.30% | -6.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 14, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 4.13% | -1.06% | 8.41% | -5.39% | -5.25% | 4.61% |
FCF Yield | 6.17% | 8.73% | 8.32% | 10.86% | 5.96% | 5.70% |
Buyback Yield / Dilution | -1.09% | -0.60% | -0.68% | -5.83% | -4.90% | -16.89% |